Enlivex Seeks Shareholder Approval for New 1-for-13 to 1-for-16 Reverse Split and Up to 1-for-1,000 Additional Splits to Avoid Nasdaq Delisting
ENLV is trading near its 52-week low of $0.38 (2.7% above the low).
Summary
Enlivex is seeking shareholder approval for a new reverse split (1-for-13 to 1-for-16) and authority for up to 1-for-1,000 in additional splits over 12 months to regain Nasdaq compliance. The stock has been below $1.00 since September 10, 2026, and a delisting determination could come as early as October 21, 2026.
Key Events · Corporate Governance and Compliance · ENLV
-
New Reverse Split Proposal
Shareholders will vote on a reverse split at a ratio of 1-for-13 to 1-for-16, to be effected as soon as practicable after approval. The Board will determine the final ratio within that range.
-
Additional Split Authority Up to 1-for-1,000
The proposal also authorizes the Board to effect one or more additional reverse splits at an aggregate ratio of 1-for-2 to 1-for-1,000 within 12 months following the Meeting, without another shareholder vote.
-
Nasdaq Delisting Risk
The stock has closed below the $1.00 minimum bid price every trading day since September 10, 2026. If it remains below $1.00 through October 21, 2026, Nasdaq will issue a Staff delisting determination.
-
Meeting and Record Date Changes
The Extraordinary General Meeting was moved from October 14 to October 16, 2026, and the record date was changed from October 1 to October 5, 2026.
Analysis · ENLV · Life Sciences
Enlivex is asking shareholders to approve a second reverse split — this time at a ratio of 1-for-13 to 1-for-16 — after the stock has traded below Nasdaq's $1.00 minimum bid price every day since September 10, 2026. The company also wants authority to execute additional reverse splits of up to 1-for-1,000 over the next 12 months without another shareholder vote. The filing states that if the bid price stays below $1.00 through October 21, 2026, Nasdaq will issue a delisting determination. This is a critical compliance vote: without the split, the company faces delisting, which would reduce liquidity, institutional interest, and its ability to raise capital. The stock is currently at $0.39, near its 52-week low of $0.38.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.5% of the 1055 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENLV was trading at $0.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.8M. The 52-week trading range was $0.38 to $27.15. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.